3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Fallopian Tube Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms
2
Uveal Melanoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Melanoma
1
Gastrointestinal Stromal Tumors
1
Disorders of Sex Development
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
235
Pemetrexed
214
Paclitaxel
160
Cisplatin
150
pembrolizumab
145
Erlotinib Hydrochloride
141
Docetaxel
133
Gemcitabine
94
Bevacizumab
85
Nivolumab
72
Radiotherapy
62
atezolizumab
40
Radiosurgery
37
Afatinib
37
osimertinib
35
130-nm albumin-bound paclitaxel
35
Cetuximab
34
durvalumab
33
Ipilimumab
32
Gefitinib
31
Albumin-Bound Paclitaxel
29
Vinorelbine
23
Taxes
22
Etoposide
20
Crizotinib
19
Radiation
17
Sorafenib
16
Cyclophosphamide
16
Dexamethasone
15
Magnetic Resonance Spectroscopy
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Non-Small-Cell Lung
×
STA 9090
×
Clear all
NCT01798485
2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3
Terminated
696 enrolled
28 charts